Partners Group Acquires Pharmathen from BC Partners
July 19, 2021
Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.
- Buyers
- Partners Group
- Targets
- Pharmathen
- Sellers
- BC Partners, VNK Capital Ltd
- Industry
- Pharmaceuticals
- Location
- Attica, Greece
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Olympus Partners Acquires PAI Pharma
February 24, 2025
Pharmaceuticals
Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.
-
Enhanced Healthcare Partners & Bourne Partners Strategic Capital Acquire Pharmaceutical Associates, Inc.
November 6, 2019
Pharmaceuticals
Enhanced Healthcare Partners (EHP), together with Bourne Partners Strategic Capital (BPSC), announced the acquisition of Pharmaceutical Associates, Inc. (PAI), a U.S. manufacturer of generic liquid and unit-dose pharmaceuticals. The investment will provide growth capital to expand PAI's manufacturing capacity, product lines and market footprint while leveraging BPSC's pharmaceutical network and EHP's healthcare investment experience.
-
GHO Capital and Partners Group Invest in Sterling Pharma Solutions
May 25, 2023
Pharmaceuticals
GHO Capital (majority owner) and Partners Group have completed an investment into GHO portfolio company Sterling Pharma Solutions, with Partners Group acquiring a significant minority stake. The transaction is supported by a consortium led by funds managed by AlpInvest Partners and Pantheon and will fund Sterling's expansion of production capacity, capability build-out and further strategic acquisitions across the UK, Europe and the US.
-
Odyssey Investment Partners Acquires ProPharma Group
September 22, 2020
Healthcare Services
Odyssey Investment Partners has agreed to acquire ProPharma Group from Linden Capital Partners. ProPharma Group, a global provider of regulatory, compliance, pharmacovigilance and medical information services headquartered in Overland Park, Kansas, will be led by CEO Dawn Sherman and the existing management team who are reinvesting alongside Odyssey to pursue organic and inorganic growth.
-
CGE Partners Invests in Datapharm
February 28, 2022
Pharmaceuticals
CGE Partners has made a growth investment in Datapharm, the UK-based provider of regulatory-driven medicines information and software (including the electronic medicines compendium, emc). The investment will partner with Datapharm's management to accelerate new product development, international expansion, and support strategic acquisitions.
-
STADA Acquires Biopharma's Pharmaceutical Prescription and Consumer Health Business
December 12, 2019
Pharmaceuticals
The STADA Group agreed to acquire the pharmaceutical prescription and consumer health business of Ukrainian producer Biopharma, including GMP-certified production facilities in Bila Tserkva. The deal integrates Biopharma's pharma operations into STADA's European organization, expands STADA's local production footprint in Ukraine and is subject to Ukrainian merger control; Biopharma's shareholders will retain the company's plasma business.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.